Malignant Glioma
Conditions
Brief summary
The blood brain barrier (BBB) is a major obstacle to drug delivery in the treatment of malignant brain tumors including glioblastoma multiforme (GBM). MRI-guided laser ablation (MLA) has been noted to disrupt peritumoral the blood brain barrier (BBB), which may then lead to increased access of new tumor antigens to the lymphovascular system and vice versa of immune effector cells to the tumor for effective activation of the immune system, and tumor infiltration, respectively. Therefore, the combination of MK-3475 and MLA as proposed in this protocol is hypothesized to create a therapeutic combinatorial effect in which MLA increases material access to promote immune activation and then MK-3475 maximizes these tumor-specific immune reactions to impart effective tumor control.
Interventions
BIOLOGICALMK-3475
Patients currently on pembrolizumab beyond the 2 year/35 cycle limit at the time of the approval of Amendment 13 (approved 07/28/2021) may continue to receive pembrolizumab unless there is progression, toxicity or agreement by the patient and PI to come off therapy. Participants who discontinue pembrolizumab after receiving 35 doses are eligible for retreatment with pembrolizumab if they progress during follow-up provided they meet the requirements. Participants may receive an additional 17 cycles (12 months) of pembrolizumab during the Second Course Phase (Retreatment).
MLA is a minimally invasive laser surgery, which employs a small incision in the scalp and skull, through which a thin laser probe is inserted and guided by MR imaging to the core of the tumor mass where it delivers hyperthermic ablation from the core to the rim.
Sponsors
Merck Sharp & Dohme LLC
Washington University School of Medicine
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
As of Amendment 12, patients enrolled in the phase II portion of this trial will no longer be randomized. These patients will undergo MLA followed by MK-3475 treatment.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Phase I: Histologically confirmed grade III or IV malignant glioma. * Phase II: Histologically confirmed grade IV malignant glioma (GBM). \*Note: GBM variants and suspected secondary GBM are allowed for both phase I and phase II. * Unequivocal evidence of tumor progression as documented by biopsy or brain MRI scan per RANO criteria. * There must be an interval of at least 12 weeks from the completion of standard front-line therapy to study registration unless there is unequivocal evidence for tumor recurrence per RANO criteria. When the interval is less than 12 weeks, the use of perfusion imaging and/or PET scan is allowed to differentiate between unequivocal evidence of tumor recurrence and pseudoprogression. Standard front-line therapy is as described below: * For grade IV malignant gliomas (GBM): Standard front line therapy for newly diagnosed GBM must include maximal feasible surgical resection (biopsy alone allowed), radiotherapy, and temozolomide chemotherapy. If the tumor was initially diagnosed as either a grade II or III tumor and now has recurred or progressed as a grade IV GBM, it will be considered a secondary recurrent grade IV GBM and will be eligible for this study as long as prior treatment included maximal feasible surgical resection (biopsy alone allowed), radiotherapy, and temozolomide chemotherapy. * For grade III malignant gliomas with 1p 19q codeletions: Standard front line therapy for newly diagnosed grade III malignant gliomas must include maximal feasible surgical resection (biopsy alone allowed), radiotherapy, and chemotherapy (PCV or temozolomide). If the patient did not receive any or all components of the standard front line therapy as detailed above for newly diagnosed grade III gliomas and the tumor then recurred or progressed, s/he must first receive at least one prior standard therapy or any appropriate combination of the components of standard therapy as detailed above and must experience further recurrence or progression before s/he is deemed eligible for this study. If the tumor was initially diagnosed as a grade II glioma with 1p 19q codeletions and now has recurred or progressed as a grade III tumor, it will be considered a secondary recurrent grade III glioma with 1p 19q codeletions and will be eligible for this study as long as prior treatment included maximal feasible surgical resection (biopsy alone allowed), radiotherapy, and chemotherapy (PCV or temozolomide). * For grade III malignant gliomas without 1p 19q codeletions: Standard front-line therapy for newly diagnosed grade III malignant gliomas must include maximal feasible surgical resection (biopsy alone allowed), radiotherapy, and temozolomide chemotherapy. If the tumor was initially diagnosed as a grade II glioma without 1p 19q codeletions and now has recurred or progressed as a grade III tumor, it will be considered a secondary recurrent grade III glioma without 1p 19q codeletions and will be eligible for this study as long as prior treatment included maximal feasible surgical resection (biopsy alone allowed), radiotherapy, and temozolomide chemotherapy. * Candidate for MLA based on the size, location, and shape of the recurrent tumor as determined by the performing neurosurgeon. Surgical resection/debulking prior to MLA is allowed per standard of care but is not required; if the patient undergoes resection or debulking, it must have occurred at least 3 weeks prior to the first dose of MK-3475. For Phase II: if surgical resection/debulking prior to MLA is not indicated, a biopsy of the tumor will be done at the same time of MLA to obtain tumor tissue for both diagnostic purposes and immune monitoring. * Patients who have undergone a resection for recurrence will be eligible. In those who have undergone a gross total resection, the MLA will be directed at treating a peritumoral margin of 0.5-1cm surrounding the resection cavity to disrupt the BBB and potentially increase access of MK-3475 to the peritumoral infiltrating glioma cells. * At least 18 years of age. * Karnofsky ≥ 60% * Normal bone marrow and organ function as defined below: * ANC ≥ 1,500/mcL * Platelets ≥ 100,000/mcL * Hemoglobin ≥ 9 g/dL or ≥ 5.6 mmol/L * Serum creatinine ≤ 1.5 x IULN OR creatinine clearance by Cockcroft-Gault ≥ 60 mL/min for patients with serum creatinine \> 1.5 x IULN * Serum total bilirubin ≤ 1.5 x IULN OR direct bilirubin ≤ IULN for patients with total bilirubin \> 1.5 x IULN * AST (SGOT) and ALT (SGPT) ≤ 2.5 x IULN (or ≤ 5 x IULN for patients with liver metastases) * INR or PT ≤ 1.5 x IULN unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants * aPTT ≤ 1.5 x IULN unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants * Sexually active women of childbearing potential and men must agree to use contraception (as described in the protocol) prior to study entry, for the duration of study participation, and for 120 days after last dose of MK-3475. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately. * Patients with the ability to understand and willingness to sign an IRB approved written informed consent document will be enrolled into the trial. However, should a patient lose their ability to consent while participating in this study and s/he is still receiving clinical benefit from participation, s/he may continue on study with the consent of a Legally Authorized Representative.
Exclusion criteria
* Prior treatment with any anti-angiogenic agent (including bevacizumab). * Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways). * Prior treatment with a monoclonal antibody within 4 weeks prior to the first dose of MK-3475 or has not recovered (i.e. ≤ grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier. * Prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to the first dose of MK-3475 or has not recovered (i.e. ≤ grade 1 or at baseline) from adverse events due to a previously administered agent. * Note: patients with ≤ grade 2 neuropathy are an exception to this criterion and may qualify for the study. * Note: if a patient underwent major surgery, s/he must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy. * Candidates for curative resection or urgent surgical procedure(s) needed. * Presence of infratentorial lesions, brainstem lesions, or lesions that are less than 5 mm from the hyophysis or cranial nerves. * Multifocal gliomas that are bilateral. Patients with unilateral multifocal gliomas may be eligible if their multifocal disease can be treated effectively and safely in a single MLA procedure. * Presence of leptomeningeal metastases. * Recent (within 8 weeks) history of CNS hemorrhage unless the hemorrhage is located within the tumor that will be removed en total during surgical debulking or ablated during MLA. * Requires therapeutic doses of anticoagulants unless anticoagulation can be safely discontinued before surgery per standard practice (e.g. first DVD for which anticoagulation has been at least 3 months and repeat imaging demonstrates resolution of DVT) or an IVC filter can be used in place of anticoagulation. Subjects are permitted to resume anticoagulation following surgery per discretion of treating physician and/or site SOPs * Received prior local therapy (stereotactic radiosurgery, brachytherapy, or carmustine wafers) to the proposed area of MLA treatment. * Received a live vaccine or live-attenuated vaccine within 30 days prior to the first dose of MK-3475. Administration of killed vaccines is allowed. * Currently receiving any other investigational agents or has participated in a study of an investigational agent or using an investigational device within 3 weeks of the first dose of MK-3475. * A history of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-3475 or other agents used in the study. * Dexamethasone \> 4 mg daily at the time of registration * Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment (with the exception of daily dexamethasone ≤ 4 mg). * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, uncontrolled hypertension, or psychiatric illness/social situations that would limit compliance with study requirements. * Has an active autoimmune disease requiring systemic treatment within the past 2 years (i.e. with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. * Has a history of (non-infectious) pneumonitis/interstitial lung disease that required steroids or current pneumonitis/interstitial lung disease. * Pregnant and/or breastfeeding. Patient must have a negative serum or urine pregnancy test within 72 hours of study entry. * Known history of hepatitis B (e.g.,defined as hepatitis B surface antigen \[HBsAg\] reactive) or known active hepatitis C virus (e.g.,defined as HCV RNA \[qualitative\] is detected) infection. * Known history of active TB (bacillus tuberculosis). * Known history of HIV (HIV 1/2 antibodies).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maximum Tolerated Dose (MTD) of MK-3475 When Combined With MLA - Phase I Only | Completion of Cycle 1 (each cycle is 3 weeks) | The MTD is defined as the dose level immediately below the dose level at which 2 patients of a cohort (of 2 to 6 patients) experienced dose-limiting toxicity during the first cycle. Dose escalations will proceed until the MTD has been reached, or failing that, 200 mg of MK-3475 every 3 weeks will be considered the MTD. |
| Progression-free Survival (PFS) - Phase II Only | Through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days). | PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Anti-glioma Immune Response Before and After MK-3475 With MLA - Phase II Only | Up to 26 months | — |
| Correlate Intratumoral Expression of PD-L1 and the Frequency of Glioma Cell-specific Cytotoxic T Cells With PFS - Phase II Only | 6 months | — |
| Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Through 90 days after completion of treatment (up to 168 weeks) | * The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for all toxicity reporting * The only toxicities that will not be collected are those that are clearly related to MLA and/or surgery AND ALSO not related to MK-3475 * Adverse events will be tracked from start of treatment through 30 days following the last day of study treatment. Serious adverse events will be tracked for 90 days following the last dose of study treatment. |
| Identify PD-1-dependent Biomarkers in Glioma Cell-specific T Cells That Negatively Correlate With the Frequency of Glioma Cell-specific Cytotoxic T Cells and PFS - Phase II Only | Up to 2 years after completion of treatment (estimated to be up to 272 weeks) | — |
| Identify PD-1-dependent Biomarkers in Glioma Cell-specific T Cells That Negatively Correlate With the Frequency of Glioma Cell-specific Cytotoxic T Cells and OS - Phase II Only | Up to 2 years after completion of treatment (estimated to be up to 272 weeks) | — |
| Correlate Intratumoral Expression of PD-L1 and the Frequency of Glioma Cell-specific Cytotoxic T Cells With OS - Phase II Only | Up to 2 years after completion of treatment (estimated to be up to 272 weeks) | — |
| Overall Survival (OS) - Phase II Only | Through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days). | OS is defined as the duration of time from start of treatment to time of death. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Phase I: MK-3475 + MLA Dose Level 1 MK-3475 will be given at 100 mg intravenously (IV) every 3 weeks starting no more than 1 week after MLA until progression or unacceptable toxicity. | 3 |
| Phase I: MK-3475 + MLA Dose Level 2 MK-3475 will be given at 150 mg intravenously (IV) every 3 weeks starting no more than 1 week after MLA until progression or unacceptable toxicity. | 3 |
| Phase I: MK-3475 + MLA Dose Level 3 MK-3475 will be given at 200 mg intravenously (IV) every 3 weeks starting no more than 1 week after MLA until progression or unacceptable toxicity. | 3 |
| Phase II: MK-3475 + MLA MK-3475 will be given at 200 mg intravenously (IV) every 3 weeks no more than 1 week after MLA, or no more than 1 week after biopsy (if no surgical debulking). This dose was determined in the Phase I portion of the trial. | 36 |
| Phase II: MK-3475 Only MK-3475 will be given at 200 mg intravenously (IV) every 3 weeks beginning 3 weeks after surgical debulking or no more than 1 week after biopsy (if no surgical debulking). This dose was determined in the Phase I portion of the trial. | 10 |
| Total | 55 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 |
|---|---|---|---|---|---|---|
| Overall Study | Was enrolled but did not receive any MK-3475 treatment | 0 | 0 | 0 | 6 | 4 |
Baseline characteristics
| Characteristic | Phase II: MK-3475 + MLA | Phase I: MK-3475 + MLA Dose Level 1 | Phase I: MK-3475 + MLA Dose Level 2 | Phase I: MK-3475 + MLA Dose Level 3 | Total | Phase II: MK-3475 Only |
|---|---|---|---|---|---|---|
| Age, Continuous | 60 years | 57 years | 41 years | 67 years | 57 years | 56.5 years |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 36 Participants | 2 Participants | 3 Participants | 3 Participants | 54 Participants | 10 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 34 Participants | 3 Participants | 3 Participants | 3 Participants | 53 Participants | 10 Participants |
| Region of Enrollment United States | 36 participants | 3 participants | 3 participants | 3 participants | 55 participants | 10 participants |
| Sex: Female, Male Female | 19 Participants | 2 Participants | 1 Participants | 2 Participants | 31 Participants | 7 Participants |
| Sex: Female, Male Male | 17 Participants | 1 Participants | 2 Participants | 1 Participants | 24 Participants | 3 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk |
|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 3 / 3 | 2 / 3 | 1 / 3 | 26 / 30 | 5 / 6 |
| other Total, other adverse events | 3 / 3 | 3 / 3 | 3 / 3 | 30 / 30 | 6 / 6 |
| serious Total, serious adverse events | 3 / 3 | 2 / 3 | 2 / 3 | 15 / 30 | 2 / 6 |
Outcome results
Primary
Maximum Tolerated Dose (MTD) of MK-3475 When Combined With MLA - Phase I Only
The MTD is defined as the dose level immediately below the dose level at which 2 patients of a cohort (of 2 to 6 patients) experienced dose-limiting toxicity during the first cycle. Dose escalations will proceed until the MTD has been reached, or failing that, 200 mg of MK-3475 every 3 weeks will be considered the MTD.
Time frame: Completion of Cycle 1 (each cycle is 3 weeks)
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Phase I: MK-3475 + MLA | Maximum Tolerated Dose (MTD) of MK-3475 When Combined With MLA - Phase I Only | 200 mg |
Primary
Progression-free Survival (PFS) - Phase II Only
PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first.
Time frame: Through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Population: Participants are evaluable for this outcome measure if they were treated in the Phase II portion of the trial (includes Phase II MK-3475 + MLA and Phase II MK-3475 Only) and at the MTD in Phase I (MK-3475 + MLA Dose Level 3). The Phase I MTD is included with the Phase II MK-3475 + MLA arm since the patients received the same dosing of treatment.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Phase I: MK-3475 + MLA | Progression-free Survival (PFS) - Phase II Only | 5.3 months |
| Phase II: MK-3475 Only | Progression-free Survival (PFS) - Phase II Only | 2.1 months |
Secondary
Anti-glioma Immune Response Before and After MK-3475 With MLA - Phase II Only
Time frame: Up to 26 months
Population: Patients underwent pre-LITT surgery or biopsy concurrent with LITT with resulting tissue (no minimum tissue volume requirement) first determining eligibility \& any remaining tissue made available for the analyses listed in the secondary outcome measures. In practice, concurrent local biopsy was heavily favored over two stage surgeries for study participants. Biopsy provided comparatively smaller volumes of tissue \&, unfortunately ended up not providing adequate tissue for this analysis.
Secondary
Correlate Intratumoral Expression of PD-L1 and the Frequency of Glioma Cell-specific Cytotoxic T Cells With OS - Phase II Only
Time frame: Up to 2 years after completion of treatment (estimated to be up to 272 weeks)
Population: Patients underwent pre-LITT surgery or biopsy concurrent with LITT with resulting tissue (no minimum tissue volume requirement) first determining eligibility \& any remaining tissue made available for the analyses listed in the secondary outcome measures. In practice, concurrent local biopsy was heavily favored over two stage surgeries for study participants. Biopsy provided comparatively smaller volumes of tissue \&, unfortunately ended up not providing adequate tissue for this analysis.
Secondary
Correlate Intratumoral Expression of PD-L1 and the Frequency of Glioma Cell-specific Cytotoxic T Cells With PFS - Phase II Only
Time frame: 6 months
Population: Patients underwent pre-LITT surgery or biopsy concurrent with LITT with resulting tissue (no minimum tissue volume requirement) first determining eligibility \& any remaining tissue made available for the analyses listed in the secondary outcome measures. In practice, concurrent local biopsy was heavily favored over two stage surgeries for study participants. Biopsy provided comparatively smaller volumes of tissue \&, unfortunately ended up not providing adequate tissue for this analysis.
Secondary
Identify PD-1-dependent Biomarkers in Glioma Cell-specific T Cells That Negatively Correlate With the Frequency of Glioma Cell-specific Cytotoxic T Cells and OS - Phase II Only
Time frame: Up to 2 years after completion of treatment (estimated to be up to 272 weeks)
Population: Patients underwent pre-LITT surgery or biopsy concurrent with LITT with resulting tissue (no minimum tissue volume requirement) first determining eligibility \& any remaining tissue made available for the analyses listed in the secondary outcome measures. In practice, concurrent local biopsy was heavily favored over two stage surgeries for study participants. Biopsy provided comparatively smaller volumes of tissue \&, unfortunately ended up not providing adequate tissue for this analysis.
Secondary
Identify PD-1-dependent Biomarkers in Glioma Cell-specific T Cells That Negatively Correlate With the Frequency of Glioma Cell-specific Cytotoxic T Cells and PFS - Phase II Only
Time frame: Up to 2 years after completion of treatment (estimated to be up to 272 weeks)
Population: Patients underwent pre-LITT surgery or biopsy concurrent with LITT with resulting tissue (no minimum tissue volume requirement) first determining eligibility \& any remaining tissue made available for the analyses listed in the secondary outcome measures. In practice, concurrent local biopsy was heavily favored over two stage surgeries for study participants. Biopsy provided comparatively smaller volumes of tissue \&, unfortunately ended up not providing adequate tissue for this analysis.
Secondary
Overall Survival (OS) - Phase II Only
OS is defined as the duration of time from start of treatment to time of death.
Time frame: Through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Population: Participants are evaluable for this outcome measure if they were treated in the Phase II portion of the trial (includes Phase II MK-3475 + MLA and Phase II MK-3475 Only) and at the MTD in Phase I (MK-3475 + MLA Dose Level 3). The Phase I MTD is included with the Phase II MK-3475 + MLA arm since the patients received the same dosing of treatment.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Phase I: MK-3475 + MLA | Overall Survival (OS) - Phase II Only | 11.8 months |
| Phase II: MK-3475 Only | Overall Survival (OS) - Phase II Only | 5.2 months |
Secondary
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only
* The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for all toxicity reporting * The only toxicities that will not be collected are those that are clearly related to MLA and/or surgery AND ALSO not related to MK-3475 * Adverse events will be tracked from start of treatment through 30 days following the last day of study treatment. Serious adverse events will be tracked for 90 days following the last dose of study treatment.
Time frame: Through 90 days after completion of treatment (up to 168 weeks)
Population: Participants in Phase II were not evaluable for this outcome measure.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 memory impairment | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 rectal hemorrhage | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 infusion related reaction | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 cough | 1 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 3/4/5 lactic acidosis | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 pain | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 3/4/5 speech aphasia | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 lethargy | 1 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 3/4/5 appendicitis | 1 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 3/4/5 sepsis | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 bronchial infection | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 dyspnea | 1 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 3/4/5 leukocytosis | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 muscle weakness - left sided | 1 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 pneumonia | 1 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 word-finding difficulty | 1 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 muscle weakness - right sided | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 nasal congestion | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 diarrhea | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 vomiting | 1 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 tachycardia | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 blood bilirubin increased | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 dry skin | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 nausea | 1 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 agitation | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 lymphocyte count decreased | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 hyperhidrosis | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 blurred vision | 1 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 platelet count decreased | 2 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 3/4/5 peripheral motor neuropathy | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 3/4/5 cellulitis | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 weight loss | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 3/4/5 rash | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 urinary tract infection | 1 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 white blood cell decreased | 2 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 anxiety | 1 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 drooping eyes | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 hyperglycemia | 3 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 edema face | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 3/4/5 skin ulceration | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 3/4/5 hyperglycemia | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 lightheadedness | 1 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 reading comprehension difficulty | 1 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 3/4/5 planned left craniectomy | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 floaters | 1 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 confusion | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 edema limbs | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 hypoalbuminemia | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 hot flashes | 1 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 cold | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 hyponatremia | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 3/4/5 intracranial hemorrhage | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 glaucoma | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 arthritis | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 oral pain | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 hypertension | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 back pain | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 insomnia | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 3/4/5 urinary tract infection | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 chest wall pain | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 alanine aminotransferase increased | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 pressure around eyes | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 dystonia | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 3/4/5 hypotension | 1 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 dysphagia | 1 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 generalized muscle weakness | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 fatigue | 1 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 joint effusion | 1 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 3/4/5 pulmonary embolism | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 3/4/5 seizure | 1 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 right visual field cut | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 3/4/5 muscle weakness - right sided | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 hematuria | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 3/4/5 diarrhea | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 muscle weakness - upper limb | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 wound from fall | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 fall | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 pain in extremity | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 3/4/5 fracture | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 swollen eyes | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 3/4/5 altered mental status | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 fever | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 alkaline phosphatase increased | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 cognitive disturbance | 1 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 creatinine increased | 1 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 bruising | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 dizziness | 1 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 urinary incontinence | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 3/4/5 abdominal pain | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 edema cerebral | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 hyperkalemia | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 hypernatremia | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 expressive aphasia | 0 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 anemia | 1 Participants |
| Phase I: MK-3475 + MLA | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 headache | 1 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 bruising | 1 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 headache | 1 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 3/4/5 intracranial hemorrhage | 0 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 diarrhea | 0 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 lethargy | 1 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 lightheadedness | 0 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 memory impairment | 0 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 3/4/5 diarrhea | 3 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 3/4/5 peripheral motor neuropathy | 1 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 fall | 1 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 reading comprehension difficulty | 0 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 3/4/5 seizure | 1 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 dysphagia | 0 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 3/4/5 speech aphasia | 0 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 word-finding difficulty | 0 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 agitation | 1 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 nausea | 0 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 anxiety | 0 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 3/4/5 fracture | 0 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 confusion | 0 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 insomnia | 1 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 oral pain | 0 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 hematuria | 0 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 urinary incontinence | 0 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 cough | 1 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 rectal hemorrhage | 0 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 dyspnea | 0 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 wound from fall | 0 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 nasal congestion | 1 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 dry skin | 1 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 vomiting | 0 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 hyperhidrosis | 0 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 pneumonia | 0 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 3/4/5 rash | 1 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 3/4/5 skin ulceration | 1 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 edema face | 1 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 3/4/5 planned left craniectomy | 0 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 hot flashes | 0 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 edema limbs | 0 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 hypertension | 0 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 3/4/5 hypotension | 0 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 3/4/5 pulmonary embolism | 1 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 fatigue | 2 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 alanine aminotransferase increased | 1 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 3/4/5 appendicitis | 0 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 creatinine increased | 0 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 fever | 1 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 3/4/5 cellulitis | 0 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 infusion related reaction | 1 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 pain | 0 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 3/4/5 lactic acidosis | 0 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 bronchial infection | 0 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 muscle weakness - left sided | 1 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 3/4/5 leukocytosis | 0 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 muscle weakness - right sided | 1 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 3/4/5 sepsis | 0 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 alkaline phosphatase increased | 1 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 blood bilirubin increased | 0 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 tachycardia | 1 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 anemia | 1 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 lymphocyte count decreased | 3 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 platelet count decreased | 0 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 blurred vision | 0 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 weight loss | 0 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 white blood cell decreased | 1 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 hyperglycemia | 1 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 drooping eyes | 0 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 3/4/5 hyperglycemia | 0 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 urinary tract infection | 0 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 hyperkalemia | 0 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 hypernatremia | 0 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 floaters | 0 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 hypoalbuminemia | 1 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 hyponatremia | 0 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 arthritis | 0 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 glaucoma | 0 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 back pain | 1 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 chest wall pain | 1 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 dystonia | 1 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 pressure around eyes | 0 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 generalized muscle weakness | 0 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 joint effusion | 0 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 3/4/5 urinary tract infection | 1 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 3/4/5 muscle weakness - right sided | 0 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 right visual field cut | 0 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 muscle weakness - upper limb | 0 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 cold | 1 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 pain in extremity | 1 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 3/4/5 altered mental status | 1 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 swollen eyes | 0 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 cognitive disturbance | 0 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 dizziness | 1 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 edema cerebral | 1 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 3/4/5 abdominal pain | 1 Participants |
| Phase II: MK-3475 Only | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 expressive aphasia | 1 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 generalized muscle weakness | 1 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 3/4/5 cellulitis | 1 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 cold | 0 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 pneumonia | 0 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 3/4/5 sepsis | 1 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 urinary tract infection | 0 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 3/4/5 urinary tract infection | 0 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 bruising | 1 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 fall | 2 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 wound from fall | 1 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 anemia | 1 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 3/4/5 lactic acidosis | 1 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 3/4/5 leukocytosis | 1 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 tachycardia | 0 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 blurred vision | 1 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 drooping eyes | 1 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 floaters | 0 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 glaucoma | 1 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 pressure around eyes | 1 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 right visual field cut | 1 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 swollen eyes | 1 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 3/4/5 abdominal pain | 0 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 diarrhea | 1 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 3/4/5 diarrhea | 0 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 dysphagia | 0 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 nausea | 0 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 oral pain | 1 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 rectal hemorrhage | 1 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 vomiting | 0 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 edema limbs | 1 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 fatigue | 1 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 fever | 0 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 infusion related reaction | 0 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 pain | 1 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 3/4/5 appendicitis | 0 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 bronchial infection | 1 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 muscle weakness - left sided | 0 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 alanine aminotransferase increased | 0 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 alkaline phosphatase increased | 0 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 blood bilirubin increased | 1 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 creatinine increased | 1 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 lymphocyte count decreased | 2 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 platelet count decreased | 1 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 weight loss | 1 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 white blood cell decreased | 0 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 hyperglycemia | 0 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 3/4/5 hyperglycemia | 1 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 hyperkalemia | 1 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 hypernatremia | 1 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 hypoalbuminemia | 0 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 hyponatremia | 1 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 arthritis | 1 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 back pain | 1 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 chest wall pain | 0 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 dystonia | 0 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 joint effusion | 0 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 muscle weakness - right sided | 0 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 3/4/5 muscle weakness - right sided | 1 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 muscle weakness - upper limb | 1 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 pain in extremity | 0 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 3/4/5 altered mental status | 0 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 cognitive disturbance | 0 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 dizziness | 1 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 edema cerebral | 0 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 expressive aphasia | 0 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 headache | 2 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 3/4/5 intracranial hemorrhage | 1 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 lethargy | 0 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 lightheadedness | 0 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 memory impairment | 1 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 3/4/5 peripheral motor neuropathy | 0 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 reading comprehension difficulty | 0 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 3/4/5 seizure | 0 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 3/4/5 speech aphasia | 1 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 word-finding difficulty | 0 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 agitation | 0 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 anxiety | 1 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 confusion | 1 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 insomnia | 0 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 hematuria | 2 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 urinary incontinence | 1 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 cough | 1 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 dyspnea | 1 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 nasal congestion | 0 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 dry skin | 1 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 hyperhidrosis | 1 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 3/4/5 rash | 0 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 3/4/5 skin ulceration | 0 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 3/4/5 planned left craniectomy | 1 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 hot flashes | 1 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 hypertension | 1 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 3/4/5 hypotension | 0 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 3/4/5 pulmonary embolism | 0 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 1/2 edema face | 1 Participants |
| Phase I: MK-3475 + MLA Dose Level 3 | Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only | Grade 3/4/5 fracture | 1 Participants |